Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05490563 · ClinicalTrials.gov registry record · Phase 2
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
A Phase 2 study, sponsored by Seelos Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT05490563: Clinical Trial Phase 2 study, sponsored by Seelos Therapeutics.
NCT05490563 is a Phase 2 study that was terminated before completion, run by Seelos Therapeutics. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05490563, a Phase 2 study, was terminated before completion, sponsored by Seelos Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).
Primary Outcome
Mean change from baseline in Modified Scale for Assessment and Rating of Ataxia (m-SARA) total score at week 52
Interventions
- DRUG Placebo
- DRUG SLS-005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2023-11-24 |
| Phase | Phase 2 |
Why NCT05490563 stopped before completion
NCT05490563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05490563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05490563 about?
NCT05490563 is a clinical study titled "STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia". Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).
What is the current status of trial NCT05490563?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2022-06-03. Estimated completion is 2023-11-24.
What interventions are being tested in trial NCT05490563?
The interventions under investigation include: Placebo (DRUG), SLS-005 (DRUG).
Who is sponsoring clinical trial NCT05490563?
This trial is sponsored by Seelos Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05490563's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI